

Global Oncology Drugs Market, By Drug Type (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Others), By Drug Therapy (Adjuvant, Neoadjuvant and Concurrent), By Route of Administration (Oral, Intravenous, Subcutaneous, Others), By Gender (Male, Female), By Cancer Type (Lung Cancer, Stomach Cancer, Others), By Distribution Channel (Hospital Pharmacies, Others), By Region, Competition, Forecast & Opportunities, 2025

<https://marketpublishers.com/r/G2BAA87836B6EN.html>

Date: April 2020

Pages: 117

Price: US\$ 4,900.00 (Single User License)

ID: G2BAA87836B6EN

Abstracts

Global oncology drugs market is projected to grow at a brisk rate over the forecast period owing to widespread prevalence of cancer, globally. Various other related factors which are contributing to the growth of oncology drugs market include rise in geriatric population worldwide, increase in global healthcare expenditure, rising number of product approvals by regulatory bodies and growing R&D activities for the development of new cancer drugs. Furthermore, emergence of biosimilar products for cancer treatment, increasing collaborations between pharmaceutical companies and development of pipeline oncology products are providing opportunities for various oncology drug manufacturers.

Oncology includes diagnosis, prevention and treatment of cancer diseases. Oncology or anti-cancer drugs can be used alone or in combination to control or destroy neoplastic cells. These drugs have the capacity to treat various kinds of cancers including blood

cancer, liver cancer, bone cancer and breast cancer.

However, the oncology drug market also faces some restraints. Fatal effects associated with the use of cancer drugs and high cost of the drug & development process are proving a hindrance for the growth of oncology drugs market.

The global oncology drugs market is segmented based on drug type, therapy, drug therapy, route of administration, gender, cancer type, distribution channel, and region. Based on therapy, the market is segmented into chemotherapy, targeted therapy, immunotherapy, hormonal therapy and others. The chemotherapy segment holds the largest market share in global oncology drugs market owing to its ability to kill cancer cells, higher efficacy and higher survival rates. However, the immunotherapy segment is going to witness fastest growth during the forecast period as they do not harm other living cells of the body.

Based on cancer type, the lung cancer segment holds the largest share in the global oncology drugs market due to its considerable surge in prevalence across the world. Major players operating in the global oncology drugs market are AbbVie Inc, Roche Holding AG, Novartis International AG, Johnson & Johnson, Bristol-Myers Squibb Company, Celgene Corporation, Merck & Co., Inc, Pfizer Inc., Eli Lilly, AstraZeneca PLC, Takeda Pharmaceutical, Amgen, Astellas Pharma, Sanofi, Eisai, Abbott, Thermo Fisher Scientific, Astex Pharmaceutical, Daiichi Sankyo, Teva Pharmaceutical and others.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021–2025

Objective of the Study:

To analyze and forecast the market size of global oncology drugs market.

To classify and forecast global oncology drugs market based on drug type, therapy, drug therapy, route of administration, gender, cancer type, distribution channel, company and regional distribution.

To identify drivers and challenges for global oncology drugs market.

To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global oncology drugs market.

To conduct pricing analysis for global oncology drugs market.

To identify and analyze the profile of leading players operating in global oncology drugs market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of oncology drug companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. TechSci Research analyzed the presence of all major players across the globe.

TechSci Research calculated the market size of global oncology drugs market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and drug therapies for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

Oncology drugs companies and other stakeholders

Government bodies such as regulating authorities and policy makers

Organizations, forums and alliances related to oncology drugs

Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global oncology drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Market, By Drug Type:

Cytotoxic Drugs

Targeted Drugs

Hormonal Drugs

Market, By Therapy:

Chemotherapy

Targeted Therapy

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Others

Market, By Drug Therapy:

Adjuvant

Neoadjuvant

Concurrent

Market, By Route of Administration:

Oral

Intravenous

Subcutaneous

Others

Market, By Gender:

Male

Female

Market, By Cancer Type:

Lung Cancer

Stomach Cancer

Colorectal Cancer

Breast Cancer

Prostate Cancer

Liver Cancer

Esophagus Cancer

Cervical Cancer

Kidney Cancer

Bladder Cancer

Others

Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Government Hospitals

Market, By Region:

Asia-Pacific

Europe

North America

South America

Middle East

Competitive Landscape:

Company Profiles: Detailed analysis of the major companies present in global oncology drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. VOICE OF CUSTOMER

5. GLOBAL ONCOLOGY DRUGS MARKET OUTLOOK

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Drug Type (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs)

5.2.2. By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Others)

5.2.3. By Drug Therapy (Adjuvant, Neoadjuvant and Concurrent)

5.2.4. By Route of Administration (Oral, Intravenous, Subcutaneous, Others)

5.2.5. By Gender (Male, Female)

5.2.6. By Cancer Type (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, Others)

5.2.7. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Government Hospitals)

5.2.8. By Company (2019)

5.2.9. By Region

5.3. Market Attractiveness Index

6. ASIA-PACIFIC ONCOLOGY DRUGS MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Drug Type

6.2.2. By Therapy

6.2.3. By Drug Therapy

6.2.4. By Route of Administration

- 6.2.5. By Gender
- 6.2.6. By Cancer Type
- 6.2.7. By Country
- 6.3. Asia-Pacific: Country Analysis
 - 6.3.1. China Oncology Drugs Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Drug Type
 - 6.3.1.2.2. By Therapy
 - 6.3.1.2.3. By Drug Therapy
 - 6.3.1.2.4. By Route of Administration
 - 6.3.1.2.5. By Gender
 - 6.3.1.2.6. By Cancer Type
 - 6.3.2. India Oncology Drugs Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Drug Type
 - 6.3.2.2.2. By Therapy
 - 6.3.2.2.3. By Drug Therapy
 - 6.3.2.2.4. By Route of Administration
 - 6.3.2.2.5. By Gender
 - 6.3.2.2.6. By Cancer Type
 - 6.3.3. Japan Oncology Drugs Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Drug Type
 - 6.3.3.2.2. By Therapy
 - 6.3.3.2.3. By Drug Therapy
 - 6.3.3.2.4. By Route of Administration
 - 6.3.3.2.5. By Gender
 - 6.3.3.2.6. By Cancer Type
 - 6.3.4. South Korea Oncology Drugs Market Outlook
 - 6.3.4.1. Market Size & Forecast
 - 6.3.4.1.1. By Value
 - 6.3.4.2. Market Share & Forecast
 - 6.3.4.2.1. By Drug Type

- 6.3.4.2.2. By Therapy
- 6.3.4.2.3. By Drug Therapy
- 6.3.4.2.4. By Route of Administration
- 6.3.4.2.5. By Gender
- 6.3.4.2.6. By Cancer Type
- 6.3.5. Singapore Oncology Drugs Market Outlook
 - 6.3.5.1. Market Size & Forecast
 - 6.3.5.1.1. By Value
 - 6.3.5.2. Market Share & Forecast
 - 6.3.5.2.1. By Drug Type
 - 6.3.5.2.2. By Therapy
 - 6.3.5.2.3. By Drug Therapy
 - 6.3.5.2.4. By Route of Administration
 - 6.3.5.2.5. By Gender
 - 6.3.5.2.6. By Cancer Type
- 6.3.6. Australia Oncology Drugs Market Outlook
 - 6.3.6.1. Market Size & Forecast
 - 6.3.6.1.1. By Value
 - 6.3.6.2. Market Share & Forecast
 - 6.3.6.2.1. By Drug Type
 - 6.3.6.2.2. By Therapy
 - 6.3.6.2.3. By Drug Therapy
 - 6.3.6.2.4. By Route of Administration
 - 6.3.6.2.5. By Gender
 - 6.3.6.2.6. By Cancer Type

7. EUROPE ONCOLOGY DRUGS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Drug Type
 - 7.2.2. By Therapy
 - 7.2.3. By Drug Therapy
 - 7.2.4. By Route of Administration
 - 7.2.5. By Gender
 - 7.2.6. By Cancer Type
 - 7.2.7. By Country
- 7.3. Europe: Country Analysis

7.3.1. France Oncology Drugs Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Drug Type

7.3.1.2.2. By Therapy

7.3.1.2.3. By Drug Therapy

7.3.1.2.4. By Route of Administration

7.3.1.2.5. By Gender

7.3.1.2.6. By Cancer Type

7.3.2. Germany Oncology Drugs Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Drug Type

7.3.2.2.2. By Therapy

7.3.2.2.3. By Drug Therapy

7.3.2.2.4. By Route of Administration

7.3.2.2.5. By Gender

7.3.2.2.6. By Cancer Type

7.3.3. United Kingdom Oncology Drugs Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Drug Type

7.3.3.2.2. By Therapy

7.3.3.2.3. By Drug Therapy

7.3.3.2.4. By Route of Administration

7.3.3.2.5. By Gender

7.3.3.2.6. By Cancer Type

7.3.4. Italy Oncology Drugs Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Drug Type

7.3.4.2.2. By Therapy

7.3.4.2.3. By Drug Therapy

7.3.4.2.4. By Route of Administration

7.3.4.2.5. By Gender

- 7.3.4.2.6. By Cancer Type
- 7.3.5. Spain Oncology Drugs Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Drug Type
 - 7.3.5.2.2. By Therapy
 - 7.3.5.2.3. By Drug Therapy
 - 7.3.5.2.4. By Route of Administration
 - 7.3.5.2.5. By Gender
 - 7.3.5.2.6. By Cancer Type

8. NORTH AMERICA ONCOLOGY DRUGS MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Drug Type
 - 8.2.2. By Therapy
 - 8.2.3. By Drug Therapy
 - 8.2.4. By Route of Administration
 - 8.2.5. By Gender
 - 8.2.6. By Cancer Type
 - 8.2.7. By Country
- 8.3. North America: Country Analysis
 - 8.3.1. United States Oncology Drugs Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Drug Type
 - 8.3.1.2.2. By Therapy
 - 8.3.1.2.3. By Drug Therapy
 - 8.3.1.2.4. By Route of Administration
 - 8.3.1.2.5. By Gender
 - 8.3.1.2.6. By Cancer Type
 - 8.3.2. Mexico Oncology Drugs Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast

- 8.3.2.2.1. By Drug Type
- 8.3.2.2.2. By Therapy
- 8.3.2.2.3. By Drug Therapy
- 8.3.2.2.4. By Route of Administration
- 8.3.2.2.5. By Gender
- 8.3.2.2.6. By Cancer Type
- 8.3.3. Canada Oncology Drugs Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Drug Type
 - 8.3.3.2.2. By Therapy
 - 8.3.3.2.3. By Drug Therapy
 - 8.3.3.2.4. By Route of Administration
 - 8.3.3.2.5. By Gender
 - 8.3.3.2.6. By Cancer Type

9. SOUTH AMERICA ONCOLOGY DRUGS MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Drug Type
 - 9.2.2. By Therapy
 - 9.2.3. By Drug Therapy
 - 9.2.4. By Route of Administration
 - 9.2.5. By Gender
 - 9.2.6. By Cancer Type
 - 9.2.7. By Country
- 9.3. South America: Country Analysis
 - 9.3.1. Brazil Oncology Drugs Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Drug Type
 - 9.3.1.2.2. By Therapy
 - 9.3.1.2.3. By Drug Therapy
 - 9.3.1.2.4. By Route of Administration
 - 9.3.1.2.5. By Gender

- 9.3.1.2.6. By Cancer Type
- 9.3.2. Argentina Oncology Drugs Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Drug Type
 - 9.3.2.2.2. By Therapy
 - 9.3.2.2.3. By Drug Therapy
 - 9.3.2.2.4. By Route of Administration
 - 9.3.2.2.5. By Gender
 - 9.3.2.2.6. By Cancer Type
- 9.3.3. Colombia Oncology Drugs Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Drug Type
 - 9.3.3.2.2. By Therapy
 - 9.3.3.2.3. By Drug Therapy
 - 9.3.3.2.4. By Route of Administration
 - 9.3.3.2.5. By Gender
 - 9.3.3.2.6. By Cancer Type

10. MIDDLE EAST AND AFRICA ONCOLOGY DRUGS MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Drug Type
 - 10.2.2. By Therapy
 - 10.2.3. By Drug Therapy
 - 10.2.4. By Route of Administration
 - 10.2.5. By Gender
 - 10.2.6. By Cancer Type
 - 10.2.7. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Oncology Drugs Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast

- 10.3.1.2.1. By Drug Type
- 10.3.1.2.2. By Therapy
- 10.3.1.2.3. By Drug Therapy
- 10.3.1.2.4. By Route of Administration
- 10.3.1.2.5. By Gender
- 10.3.1.2.6. By Cancer Type
- 10.3.2. Saudi Arabia Oncology Drugs Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Drug Type
 - 10.3.2.2.2. By Therapy
 - 10.3.2.2.3. By Drug Therapy
 - 10.3.2.2.4. By Route of Administration
 - 10.3.2.2.5. By Gender
 - 10.3.2.2.6. By Cancer Type
- 10.3.3. UAE Oncology Drugs Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Drug Type
 - 10.3.3.2.2. By Therapy
 - 10.3.3.2.3. By Drug Therapy
 - 10.3.3.2.4. By Route of Administration
 - 10.3.3.2.5. By Gender
 - 10.3.3.2.6. By Cancer Type
- 10.3.4. Kuwait Oncology Drugs Market Outlook
 - 10.3.4.1. Market Size & Forecast
 - 10.3.4.1.1. By Value
 - 10.3.4.2. Market Share & Forecast
 - 10.3.4.2.1. By Drug Type
 - 10.3.4.2.2. By Therapy
 - 10.3.4.2.3. By Drug Therapy
 - 10.3.4.2.4. By Route of Administration
 - 10.3.4.2.5. By Gender
 - 10.3.4.2.6. By Cancer Type

11. MARKET DYNAMICS

11.1. Drivers

11.2. Challenges

12. PATENTS (NDA, ANDA)

13. MARKET TRENDS & DEVELOPMENTS

14. COMPETITIVE LANDSCAPE

14.1. Competition Outlook

14.2. Players Profiled (Leading Companies)

14.2.1. AbbVie Inc

14.2.2. Roche Holding AG

14.2.3. Novartis International AG

14.2.4. Johnson & Johnson

14.2.5. Bristol-Myers Squibb Company

14.2.6. Celgene Corporation

14.2.7. Merck & Co., Inc

14.2.8. Pfizer Inc.

14.2.9. Eli Lilly

14.2.10. AstraZeneca PLC

14.2.11. Takeda Pharmaceutical

14.2.12. Amgen

14.2.13. Astellas Pharma

14.2.14. Sanofi

14.2.15. Eisai

14.2.16. Abbott

14.2.17. Thermo Fisher Scientific

14.2.18. Astex Pharmaceutical

14.2.19. Daiichi Sankyo

14.2.20. Teva Pharmaceutical

15. STRATEGIC RECOMMENDATIONS

List Of Figures

LIST OF FIGURES

- Figure 1: Global Oncology Drugs Size, By Value (USD Million), 2015-2025F
- Figure 2: Global Oncology Drugs Size, By Drug Type (USD Million), 2015-2025F
- Figure 3: Global Oncology Drugs Share, By Route of Administration (USD Million), 2015-2025F
- Figure 4: Global Oncology Drugs Share, By Drug Therapy (USD Million), 2015-2025F
- Figure 5: Global Oncology Drugs Share, By Region (USD Million), 2015-2025F
- Figure 6: Global Oncology Drugs Share, By Company (USD Million), 2015-2025F
- Figure 7: Global Oncology Drugs Attractiveness Index, By Region, By Value, 2015-2025F
- Figure 8: Global Oncology Drugs Attractiveness Index, By Route of Administration Type, By Value, 2015-2025F
- Figure 9: North America Oncology Drugs Size, By Value (USD Million), 2015-2025F
- Figure 10: North America Oncology Drugs Size, By Drug Type (USD Million), 2015-2025F
- Figure 11: North America Oncology Drugs Share, By Route of Administration (USD Million), 2015-2025F
- Figure 12: North America Oncology Drugs Share, By Drug Therapy (USD Million), 2015-2025F
- Figure 13: North America Oncology Drugs Share, By Country (USD Million), 2015-2025F
- Figure 14: North America Oncology Drugs Attractiveness Index, By Country, By Value, 2015-2025F
- Figure 15: North America Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
- Figure 16: United States Oncology Drugs Size, By Value (USD Million), 2015-2025F
- Figure 17: United States Oncology Drugs Size, By Drug Type, 2015-2025F
- Figure 18: United States Oncology Drugs Share, By Route of Administration, 2015-2025F
- Figure 19: United States Oncology Drugs Share, By Drug Therapy, 2015-2025F
- Figure 20: United States Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F
- Figure 21: Canada Oncology Drugs Size, By Value (USD Million), 2015-2025F
- Figure 22: Canada Oncology Drugs Size, By Drug Type, 2015-2025F
- Figure 23: Canada Oncology Drugs Share, By Route of Administration, 2015-2025F
- Figure 24: Canada Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 25: Canada Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 26: Mexico Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 27: Mexico Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 28: Mexico Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 29: Mexico Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 30: Mexico Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 31: Europe Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 32: Europe Oncology Drugs Size, By Drug Type (USD Million), 2015-2025F

Figure 33: Europe Oncology Drugs Share, By Route of Administration (USD Million), 2015-2025F

Figure 34: Europe Oncology Drugs Share, By Drug Therapy (USD Million), 2015-2025F

Figure 35: Europe Oncology Drugs Share, By Country (USD Million), 2015-2025F

Figure 36: Europe Oncology Drugs Attractiveness Index, By Country, By Value, 2015-2025F

Figure 37: Europe Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 38: Russia Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 39: Russia Kingdom Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 40: Russia Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 41: Russia Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 42: Russia Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 43: United Kingdom Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 44: United Kingdom Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 45: United Kingdom Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 46: United Kingdom Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 47: United Kingdom Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 48: Italy Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 49: Italy Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 50: Italy Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 51: Italy Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 52: Italy Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 53: Germany Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 54: Germany Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 55: Germany Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 56: Germany Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 57: Germany Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 58: Spain Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 59: Spain Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 60: Spain Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 61: Spain Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 62: Spain Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 63: France Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 64: France Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 65: France Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 66: France Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 67: France Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 68: Asia – Pacific Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 69: Asia – Pacific Oncology Drugs Size, By Drug Type(USD Million), 2015-2025F

Figure 70: Asia – Pacific Oncology Drugs Share, By Route of Administration (USD Million), 2015-2025F

Figure 71: Asia – Pacific Oncology Drugs Share, By Drug Therapy (USD Million), 2015-2025F

Figure 72: Asia – Pacific Oncology Drugs Share, By Country (USD Million), 2015-2025F

Figure 73: Asia – Pacific Oncology Drugs Attractiveness Index, By Country, By Value, 2015-2025F

Figure 74: Asia – Pacific Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 75: China Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 76: China Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 77: China Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 78: China Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 79: China Oncology Drugs Share, By Strength, 2015-2025F

Figure 80: China Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 81: India Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 82: India Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 83: India Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 84: India Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 85: India Oncology Drugs Attractiveness Index, By Route of Administration, By

Value, 2015-2025F

Figure 86: Australia Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 87: Australia Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 88: Australia Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 89: Australia Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 90: Australia Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 91: Japan Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 92: Japan Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 93: Japan Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 94: Japan Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 95: Japan Oncology Drugs Share, By Strength, 2015-2025F

Figure 96: Japan Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 97: Singapore Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 98: Singapore Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 99: Singapore Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 100: Singapore Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 101: Singapore Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 102: South Korea Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 103: South Korea Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 104: South Korea Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 105: South Korea Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 106: South Korea Oncology Drugs Share, By Strength, 2015-2025F

Figure 107: South Korea Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 108: Middle East and Africa Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 109: Middle East and Africa Oncology Drugs Size, By Drug Type(USD Million), 2015-2025F

Figure 110: Middle East and Africa Oncology Drugs Share, By Route of Administration (USD Million), 2015-2025F

Figure 111: Middle East and Africa Oncology Drugs Share, By Drug Therapy (USD Million), 2015-2025F

Figure 112: Middle East and Africa Oncology Drugs Share, By Country (USD Million), 2015-2025F

Figure 113: Middle East and Africa Oncology Drugs Attractiveness Index, By Country,

By Value, 2015-2025F

Figure 114: Middle East and Africa Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 115: Saudi Arabia Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 116: Saudi Arabia Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 117: Saudi Arabia Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 118: Saudi Arabia Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 119: Saudi Arabia Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 120: UAE Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 121: UAE Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 122: UAE Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 123: UAE Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 124: UAE Oncology Drugs Share, By Strength, 2015-2025F

Figure 125: UAE Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 126: South Africa Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 127: South Africa Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 128: South Africa Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 129: South Africa Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 130: South Africa Oncology Drugs Share, By Strength, 2015-2025F

Figure 131: South Africa Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 132: Kuwait Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 133: Kuwait Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 134: Kuwait Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 135: Kuwait Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 136: Kuwait Oncology Drugs Share, By Strength, 2015-2025F

Figure 137: Kuwait Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 138: South America Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 139: South America Oncology Drugs Size, By Drug Type (USD Million), 2015-2025F

Figure 140: South America Oncology Drugs Share, By Route of Administration (USD Million), 2015-2025F

Figure 141: South America Oncology Drugs Share, By Drug Therapy (USD Million), 2015-2025F

Figure 142: South America Oncology Drugs Share, By Country (USD Million), 2015-2025F

Figure 143: South America Oncology Drugs Attractiveness Index, By Country, By Value, 2015-2025F

Figure 144: South America Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 145: Brazil Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 146: Brazil Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 147: Brazil Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 148: Brazil Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 149: Brazil Oncology Drugs Share, By Strength, 2015-2025F

Figure 150: Brazil Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 151: Argentina Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 152: Argentina Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 153: Argentina Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 154: Argentina Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 155: Argentina Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

Figure 156: Colombia Oncology Drugs Size, By Value (USD Million), 2015-2025F

Figure 157: Colombia Oncology Drugs Size, By Drug Type, 2015-2025F

Figure 158: Colombia Oncology Drugs Share, By Route of Administration, 2015-2025F

Figure 159: Colombia Oncology Drugs Share, By Drug Therapy, 2015-2025F

Figure 160: Colombia Oncology Drugs Share, By Strength, 2015-2025F

Figure 161: Colombia Oncology Drugs Attractiveness Index, By Route of Administration, By Value, 2015-2025F

COMPANIES MENTIONED

1. AbbVie Inc
2. Roche Holding AG
3. Novartis International AG
4. Johnson & Johnson
5. Bristol-Myers Squibb Company
6. Celgene Corporation
7. Merck & Co., Inc
8. Pfizer Inc.
9. Eli Lilly
10. AstraZeneca PLC

11. Takeda Pharmaceutical
12. Amgen
13. Astellas Pharma
14. Sanofi
15. Eisai
16. Abbott
17. Thermo Fisher Scientific
18. Astex Pharmaceutical
19. Daiichi Sankyo
20. Teva Pharmaceutical

I would like to order

Product name: Global Oncology Drugs Market, By Drug Type (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Others), By Drug Therapy (Adjuvant, Neoadjuvant and Concurrent), By Route of Administration (Oral, Intravenous, Subcutaneous, Others), By Gender (Male, Female), By Cancer Type (Lung Cancer, Stomach Cancer, Others), By Distribution Channel (Hospital Pharmacies, Others), By Region, Competition, Forecast & Opportunities, 2025

Product link: <https://marketpublishers.com/r/G2BAA87836B6EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2BAA87836B6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970